Yahoo Finance Live's Seana Smith checks out several stocks trending in the after-hours trading session. Read More...
Benzinga
Sorrento Touts Positive Early-Stage Trial Data From Oral COVID-19 Therapy
Sorrento Therapeutics Inc (NASDAQ: SRNE) released topline Phase 2 SAD/MAD study data of its oral main protease (Mpro) inhibitor, STI-1558, conducted in 58 healthy volunteers in Australia. The SAD portion of the study evaluated doses from 300 mg to 2,000 mg, and the MAD portion evaluated 300 mg, 600 mg, or 800 mg BID (twice daily) for 7.5 days. In addition to the Mpro inhibition, which can block viral replication, STI-1558 has cathepsin L inhibition, preventing viral entry into the host cell. Rel
